Safety and Acceptability of Thermal Ablation for Treatment of Human Papillomavirus Among Women Living With HIV in Western Kenya

Chemtai Mungo, Cirilus Ogollah Osongo, Jeniffer Ambaka, Magdalene A Randa, Jackton Omoto, Craig R Cohen, Megan Huchko, Chemtai Mungo, Cirilus Ogollah Osongo, Jeniffer Ambaka, Magdalene A Randa, Jackton Omoto, Craig R Cohen, Megan Huchko

Abstract

Purpose: The WHO now recommends thermal ablation as an alternative to cryotherapy within "screen-and-treat" cervical cancer programs in low- and middle-income countries (LMICs). We conducted a safety and acceptability clinical trial of thermal ablation in a Kenyan Ministry of Health hospital among women living with HIV (WLWH; ClinicalTrials.gov identifier: NCT04191967).

Methods: Between August 2019 and February 2020, WLWH age 25-65 years underwent human papillomavirus (HPV) self-collection in western Kenya. HPV-positive women underwent visual inspection with acetic acid, biopsy, and treatment with thermal ablation performed by a nonphysician clinician, if eligible by standard guidelines. A questionnaire was administered after treatment to assess for pain and treatment acceptability. Adverse events (AEs) were evaluated 4-6 weeks after treatment with a standardized grading tool.

Results: A total of 293 HPV-positive WLWH underwent thermal ablation in the study period. The mean age was 40.4 years (standard deviation, 8.7 years). After treatment, 15 (5.1%), 231 (78.8%), 42 (14.3%), and 5 (1.8%) reported none, mild, moderate, and severe pain with treatment, respectively. At follow-up, spotting, vaginal discharge, and pelvic pain were reported by 99 (37.8%), 258 (98.5%), and 46 (17.6%), respectively, for a median of 3.3 (interquartile range [IQR], 2-3), 14 (IQR, 7-21), and 7 (IQR, 3-7) days, respectively. Most participants graded their AEs as mild (grade 1): 94 (95.0%) for bleeding, 125 (48.5%) for vaginal discharge, and 37 (80.4%) for pelvic pain. No grade 3 or 4 AEs were reported. The vast majority (99.2%) were satisfied with the treatment and would recommend it to a friend.

Conclusion: Thermal ablation performed by nonphysicians in the public health sector in Kenya proved safe and highly acceptable in treating HPV-positive WLWH.

Conflict of interest statement

Craig R. Cohen

Honoraria: Lupin Pharmaceuticals, Miyarisan Pharmaceutical

No other potential conflicts of interest were reported.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018.
    1. Joshi S, Sankaranarayanan R, Muwonge R, et al. Screening of cervical neoplasia in HIV-infected women in India. AIDS. 2013;27:607–615.
    1. Gichangi PB, Bwayo J, Estambale B, et al. Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS. 2003;17:1963–1968.
    1. Denny L, Quinn M, Sankaranarayanan R: Chapter 8: Screening for cervical cancer in developing countries. Vaccine 24:71-77, 2006 (suppl 3)
    1. World Health Organization WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. 2013
    1. Sankaranarayanan R, Rajkumar R, Esmy PO, et al. Effectiveness, safety and acceptability of ‘see and treat’ with cryotherapy by nurses in a cervical screening study in India. Br J Cancer. 2007;96:738–743.
    1. Nene BM, Hiremath PS, Kane S, et al. Effectiveness, safety, and acceptability of cryotherapy by midwives for cervical intraepithelial neoplasia in Maharashtra, India. Int J Gynaecol Obstet. 2008;103:232–236.
    1. Santesso N, Schünemann H, Blumenthal P, et al. World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2012;118:97–102.
    1. Castle PE, Murokora D, Perez C, et al. Treatment of cervical intraepithelial lesions. Int J Gynaecol Obstet. 2017;138(suppl 1):20–25.
    1. Msyamboza KP, Phiri T, Sichali W, et al. Cervical cancer screening uptake and challenges in Malawi from 2011 to 2015: Retrospective cohort study. BMC Public Health. 2016;16:806.
    1. Binagwaho A, Garcia PJ, Gueye B, et al. Eliminating deaths from cervical cancer-report of a panel at the 7th Annual Symposium on Global Cancer Research, a satellite meeting at the Consortium of Universities for Global Health 10th Annual Meeting. J Glob Oncol
    1. Maza M, Schocken CM, Bergman KL, et al: Cervical Precancer treatment in low- and middle-income countries: A technology overview. J Glob Oncol .
    1. Dolman L, Sauvaget C, Muwonge R, et al. Meta-analysis of the efficacy of cold coagulation as a treatment method for cervical intraepithelial neoplasia: A systematic review. BJOG. 2014;121:929–942.
    1. World Health Organization: WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. 2019.
    1. Randall TC, Sauvaget C, Muwonge R, et al. Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesions. Prev Med. 2019;118:81–91.
    1. Loobuyck HA, Duncan ID. Destruction of CIN 1 and 2 with the Semm cold coagulator: 13 years’ experience with a see-and-treat policy. Br J Obstet Gynaecol. 1993;100:465–468.
    1. Singh P, Loke K-L, Hii J, et al. Cold coagulation versus cryotherapy for treatment of cervical intraepithelial neoplasia: Results of a prospective randomized trial. J Gynecol Surg. 1988;4:211–221.
    1. Goodman JD, Sumner D. Patient acceptability of laser and cold coagulation therapy for pre-malignant disease of the uterine cervix. Br J Obstet Gynaecol. 1991;98:1168–1171.
    1. Hussein IY, Galloway RK. Use of the cold coagulator in the treatment of cervical intra-epithelial neoplasia. J Obstet Gynaecol. 1985;6:62–64.
    1. de Cristofaro D, Trioni G, Pezzoli C: Treatment of CIN with cold coagulation. J Exp Clin Cancer Res 9:133, 1990.
    1. Viviano M, Kenfack B, Catarino R, et al. Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa. BMC Womens Health. 2017;17:2.
    1. Naud PSV, Muwonge R, Passos EP, et al. Efficacy, safety, and acceptability of thermocoagulation for treatment of cervical intraepithelial neoplasia in a hospital setting in Brazil. Int J Gynaecol Obstet. 2016;133:351–354.
    1. Pinder LF, Parham GP, Basu P, et al. Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: Pilot phase of a randomised controlled trial. Lancet Oncol. 2020;21:175–184.
    1. Tiruneh FN, Chuang KY, Ntenda PAM, et al. Individual-level and community-level determinants of cervical cancer screening among Kenyan women: A multilevel analysis of a Nationwide survey. BMC Womens Health. 2017;17:109.
    1. Cure Medical: Thermocoagulator kits
    1. Sellors JW, Sankaranarayanan R (eds): Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginner’s Manual. Lyon, France, World Health Organization, 2003.
    1. Division of AIDS, National Institute of Allergy and Infectious Diseases: Division of AIDS Table Grading the Severity of Adult and Pediatric Adverse Events. 2004. .
    1. Castro W, Gage J, Gaffikin L, et al: Effectiveness, safety and acceptability of cryotherapy: A systematic literature review. Cervical Cancer Prevention Issues in Depth, Seattle, WA, Alliance for Cervical Cancer Prevention, 2003.
    1. Lewis KDC, Sellors JW, Dawa A, et al. Report on a cryotherapy service for women with cervical intraepithelial neoplasia in a district hospital in western Kenya. Afr Health Sci. 2011;11:370–376.
    1. Division of AIDS, National Institute of Allergy and Infectious Diseases: Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events: Corrected version 2.1. .

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe